Who we are

Paul Janssen Futurelab Leiden is an initiative of Leiden University Medical Center to create International blended learning program for tomorrow’s leaders in Biomedical science. We offer professional learning programs with a unique blend of online education and on-campus training to improve the processes for discovery and development of new medical interventions.

Our approach to professional learning

Treating diseases has become increasingly complex. A multidisciplinary approach – from science to business – is becoming increasingly important to address these challenges . We offer inspiring blended courses to help guide the next generation of leaders in life sciences through the layered skill set that they will need to make their own. Our mantra is learning by doing and our courses stimulate active participation with a wide variety of teaching methods, such as animations, expert interviews, self-assessment tools, polls and , teaching cases. and (online) discussions.

 

We aim to provide 3 key professional learning experiences:

  1. Interdisciplinary team work with real-world case studies
  2. Inspiring ‘What Really Happened’ sessions with experts from the field
  3. Sharing expertise with colleagues and key players from industry, academia, and authority

What’s in a name

Dr. Paul Janssen (1926 - 2003), founder of Janssen Pharmaceutical, was a pioneer in the field of biomedical research, as well as a highly successful entrepreneur. With a drive and curiosity that led him to pursue biomedical research, medicine, chemistry, pharmacology, and entrepreneurship, he discovered, developed, and brought to market many new medicinal products which significantly impacted the lives of many patients. At Paul Janssen Futurelab Leiden, Dr. Janssen’s multidisciplinary approach serves as a role model to inspire future generations of entrepreneurial researchers.

On January 30, 2016, Paul Janssen Futurelab Leiden signed an agreement with Baroness Dora Janssen-Arts to use the name for this initiative. We are, and will remain, an independent non-profit organization and have no financial ties with companies. We do collaborate closely with pharmaceutical and life sciences companies, with authorities and other academic institutions, for instance, for the development of teaching cases that are used in the courses and scholarships that are awarded to promising candidates who would otherwise not be able to join the courses.

Our alumni

Our alumni are more than 150 professionals from over 10 countries in Africa, Asia, Europe, Middle East and USA who are working on the development of new medical interventions from industry, in academia, industry, at authorities etc have already participated in our courses. The on-campus has created a lasting experience and a solid network among our alumni and contributors. Will you be part of the Future?

Our contributors

We are fortunate to have many excellent contributors who help to make the on-campus course a success. Below are a few contributors who have shared their expertise with our participants in guest lectures and discussions during the 2017 course. Visit the contributor's page to see all contributors.

A selection of our contributors

Marc Martens

Marc Martens

Head of Bird & Bird's Regulatory, Public & Administrative Law group in Brussels


Bird & Bird

Aliki Nichogiannopoulou

Aliki Nichogiannopoulou

Director


European Patent Office

Ton van der Hoven

Ton van der Hoven

CEO


SurgVision BV

Bruno Vandermeulen

Bruno Vandermeulen

IP Lawyer - Member of the Brussels Bar


Independent IP practitioner

On-campus

Nacer Lounis

Nacer Lounis

Senior Principal Scientist


Janssen Pharmaceutica

On-campus

Tine de Marez

Tine de Marez

Senior Director, Compound Development Team Leader TB


Johnson & Johnson

Bert Leufkens

Bert Leufkens

Professor of Pharmaceutical Policy and Regulatory Science and Former Chair of Medicines Evaluation Board


Utrecht Institute for Pharmaceutical Sciences (UIPS)

Henk Schuring

Henk Schuring

VP-Head Rare Nephrology


Sanofi Genzyme

Sjaak Bot

Sjaak Bot

VP, Head of EMEA Regulatory Affairs


Janssen

Bernd van der Meulen

Bernd van der Meulen

Professor of Comparative Food Law


European Institute for Food Law / Renmin University of China Law School

Frank Landolt

Frank Landolt

Chief Counsel Legal & Intellectual Property


Confo Therapeutics

On-campus

Erik Niks

Erik Niks

Neurologist - Pediatric neurologist


Leiden University Medical Center

On-campus

Piet Hinoul

Piet Hinoul

Global Head, Pre-Clinical, Clinical and Medical Affairs


J&J Ethicon

On-campus

Ad Sitsen

Ad Sitsen

Owner


ClinPharMed Consultancy for Drug Development

Eline Bunnik

Eline Bunnik

Assistant professor Medical Ethics and Philosophy of Medicine


Erasmus MC

Maurits Westerik

Maurits Westerik

IE/IT lawyer


Coupry

Bart Swinkels

Bart Swinkels

Partner


NLO

Karin Verzijden

Karin Verzijden

Food and Pharma Lawyer


Axon Lawyers

On-campus

Ineke Jonker-Hoogerkamp

Ineke Jonker-Hoogerkamp

Consultant Regulatory Affairs and Drug Development


Paul Janssen Futurelab & Eagle Pharma Consult

Kees Recourt

Kees Recourt

Investment Manager


Mibiton Foundation

Paul Stoffels

Paul Stoffels

Chief scientific officer


Johnson & Johnson

Tom Huizinga

Tom Huizinga

Head of the Department of Rheumatology


Leiden University Medical Centre

On-campus

Marcel Kenter

Marcel Kenter

Director


Paul Janssen Futurelab Leiden

On-campus

Koen Andries

Koen Andries

VP Scientific Fellow Infectious Diseases Discovery


Janssen Pharmaceutica NV

On-campus

Andreas Wallnöfer

Andreas Wallnöfer

General Partner


BioMed Partners Venture Capital (former Head of Clinical Research & Exploratory Development at F. Hoffmann-La Roche Ltd.)

On-campus

Justin Hay

Justin Hay

Pharmacokinetics Assessor


Medicines and Healthcare products Regulatory Agency

On-campus

André Elferink

André Elferink

Clinical epidemiologist


Dutch Medicines Evaluation Board

On-campus

Rob Zuiker

Rob Zuiker

Senior Clinical Scientist


CHDR

On-campus

Barbara J. van Zwieten-Boot

Barbara J. van Zwieten-Boot

Vice Chair


Medicines Evaluation Board, The Netherlands

Hans-Georg Eichler

Hans-Georg Eichler

Senior Medical Officer


European Medicines Agency

On-campus

Robert Klautz

Robert Klautz

Thoracic Surgeon


Leiden University Medical Centre

On-campus

Matthijs Moerland

Matthijs Moerland

Research Director Translational Biomarkers


CHDR

Joris Rotmans, MD, PhD

Joris Rotmans, MD, PhD

internist-nephrologist


LUMC

On-campus

Janneke Meulenberg

Janneke Meulenberg

CEO


Arthrogen

Inge de Lepeleire

Inge de Lepeleire

Director Translational Pharmacology


MSD Europe

On-campus

Koos Burggraaf

Koos Burggraaf

Research Director CVS & Metabolism


CHDR

Johan Garssen

Johan Garssen

Director Immunology Platform


Danone/Nutricia Research

On-campus

Ingrid de Visser

Ingrid de Visser

Senior Clinical Scientist


CHDR

Rick Kuntz

Rick Kuntz

Senior Vice President and Chief Scientific, Clinical and Regulatory Officer


Medtronic

On-campus

Paul de Koning

Paul de Koning

Exploratory Development Expert


Former Head Clinical Pharmacology & Exploratory Development Astellas

On-campus

Geert Jan Groeneveld

Geert Jan Groeneveld

Research Director CNS


CHDR

Oliver Bisazza

Oliver Bisazza

Director Regulatory Policy


Medtronic

Saco de Visser

Saco de Visser

Teacher and Clinical Pharmacologist


Paul Janssen Futurelab Leiden

On-campus

Adam Cohen

Adam Cohen

CEO and clinical pharmacologist


Centre for Human Drug Research

Richard Shull

Richard Shull

Head of Deal Structuring and Trading Fundamentals


Shell

Pierre Peeters

Pierre Peeters

Former site head early stage development


Organon

Our team

Who we are

Marcel Kenter

Director

Who we are

Ineke Jonker

Teacher

Who we are

Saco de Visser

Teacher Clinical Development

Who we are

Bruno vanderMeulen

Teacher Intellectual Property

Who we are

Thijs van Iersel

Multimedia Developer

Who we are

Kees Recourt

Developer Intellectual Property course

Building towards an advanced master

Behind the scenes we are developing new courses and are building towards an advanced master program. The advanced master revolves around the main theme: Improving the discovery and development of new medical interventions and will incorporate topics in biomedical science, clinical development, leadership and entrepreneurship. A blended course can be done as a stand-alone course or blended courses from several topics can be combined to will earn a recognized master degree. Each blended course is a part-time module consisting of a multi-week online course (with an average work load of 5 hours per week) and an 1 or 2 on-campus courses. The blended courses are designed for graduated biomedical post-academic professionals with working experience in academia, industry or at authorities. Combine professional learning with your career and personal life thanks to the part-time character of the blended courses and take the next step in your career.

An initiative of Leiden University Medical Center

PJ Futurelab: An initative of LUMC

 

 

 

Articles from our blog

This may be interesting for you

Dora Janssen launches Paul Janssen Futurelab Leiden

Baroness Dora Janssen-Arts — widow of Dr. Paul Janssen — officially announced the launch of Paul Janssen Futurelab Leiden, an international training program providing blended learning (online and on-campus) to biomedical professionals with an entrepreneurial spirit. This new training program is an initiative of the Leiden University Medical Center in collaboration with the Center for Human Drug Research and Leiden University, sponsored by grants from ZonMw and Health~Holland. Listen to Baroness Dora Janssen's message for the next generation of scientists.

How to become a maker of tomorrow’s medicines using Real Options Theory

Paul Janssen Futurelab Leiden offers a new international blended education & training program for talented biomedical scientists on the development of novel medical interventions using the Real Options Theory. The aim is that these future chief scientific officers will change the entire drug development process.